{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:00:38Z","timestamp":1774890038456,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Prime Ministers Research Fellowship"},{"name":"Param Hansa Philanthropies"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention Research Institute of Texas","doi-asserted-by":"crossref","award":["RR210080"],"award-info":[{"award-number":["RR210080"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences of the NIH","doi-asserted-by":"crossref","award":["R35GM155458"],"award-info":[{"award-number":["R35GM155458"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15691-2","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:24:41Z","timestamp":1771824281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER+ breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Yijia","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarthak","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit Kumar","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason T.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"6","key":"15691_CR1","first-page":"438","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"15691_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37(4):496\u2013513.","journal-title":"Cancer Cell"},{"issue":"9","key":"15691_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrclinonc.2015.99","volume":"12","author":"CD Hart","year":"2015","unstructured":"Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015;12(9):541\u201352.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"15691_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22(1):109.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"15691_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000508675","volume":"15","author":"AD Hartkopf","year":"2020","unstructured":"Hartkopf AD, Grischke EM, Brucker SY. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care. 2020;15(4):347\u201354.","journal-title":"Breast Care"},{"issue":"12","key":"15691_CR6","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","volume":"24","author":"HS Rugo","year":"2018","unstructured":"Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res. 2018;24(12):2804\u201311.","journal-title":"Clin Cancer Res"},{"key":"15691_CR7","first-page":"1","volume":"4","author":"C Criscitiello","year":"2010","unstructured":"Criscitiello C, Fumagalli D, Saini KS, Loi S. Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. Onco Targets Ther. 2010;4:1\u201311.","journal-title":"OncoTargets Ther"},{"key":"15691_CR8","doi-asserted-by":"crossref","unstructured":"Manna S, Holz MK. Tamoxifen action in ER-negative breast cancer. Signal Transduct Insights. 2016;5:STI\u2013S29901.","DOI":"10.4137\/STI.S29901"},{"issue":"3","key":"15691_CR9","doi-asserted-by":"publisher","first-page":"zcab027","DOI":"10.1093\/narcan\/zcab027","volume":"3","author":"S Sahoo","year":"2021","unstructured":"Sahoo S, Mishra A, Kaur H, Hari K, Muralidharan S, Mandal S, et al. A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cells. NAR Cancer. 2021;3(3):zcab027.","journal-title":"NAR Cancer"},{"key":"15691_CR10","doi-asserted-by":"publisher","first-page":"797261","DOI":"10.3389\/fimmu.2021.797261","volume":"12","author":"S Sahoo","year":"2021","unstructured":"Sahoo S, Nayak SP, Hari K, Purkait P, Mandal S, Kishore A, et al. Immunosuppressive traits of the hybrid epithelial\/mesenchymal phenotype. Front Immunol. 2021;12:797261.","journal-title":"Front Immunol"},{"key":"15691_CR11","doi-asserted-by":"crossref","unstructured":"Zhu L, Zou J, Zhao Y, Jiang X, Wang Y, Wang X, et al. ER-$$\\alpha $$36 mediates cisplatin resistance in breast cancer cells through EGFR\/HER-2\/ERK signaling pathway. J Exp Clin Cancer Res. 2018;37(1):123.","DOI":"10.1186\/s13046-018-0798-z"},{"key":"15691_CR12","doi-asserted-by":"crossref","unstructured":"Wang Q, Jiang J, Ying G, Xie XQ, Zhang X, Xu W, et al. Tamoxifen enhances stemness and promotes metastasis of ER$$\\alpha $$36+ breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 2018;28(3):336\u201358.","DOI":"10.1038\/cr.2018.15"},{"key":"15691_CR13","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.2147\/OTT.S217794","volume":"12","author":"J Tian","year":"2019","unstructured":"Tian J, Sun HX, Li YC, Jiang L, Zhang SL, Hao Q. LOXL 2 promotes the epithelial\u2013mesenchymal transition and malignant progression of cervical cancer. Onco Targets Ther. 2019;12:8947\u201354.","journal-title":"OncoTargets Ther"},{"issue":"42","key":"15691_CR14","doi-asserted-by":"publisher","first-page":"30000","DOI":"10.1074\/jbc.C113.502310","volume":"288","author":"HJ Moon","year":"2013","unstructured":"Moon HJ, Finney J, Xu L, Moore D, Welch DR, Mure M. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. J Biol Chem. 2013;288(42):30000\u20138.","journal-title":"J Biol Chem"},{"issue":"14","key":"15691_CR15","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/onc.2016.358","volume":"36","author":"DH Peng","year":"2017","unstructured":"Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, et al. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene. 2017;36(14):1925\u201338.","journal-title":"Oncogene"},{"issue":"7","key":"15691_CR16","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3390\/cancers13071609","volume":"13","author":"Y Deng","year":"2021","unstructured":"Deng Y, Chakraborty P, Jolly MK, Levine H. A theoretical approach to coupling the epithelial-mesenchymal transition (EMT) to extracellular matrix (ECM) stiffness via LOXL2. Cancers. 2021;13(7):1609.","journal-title":"Cancers"},{"issue":"17","key":"15691_CR17","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-15-2461","volume":"22","author":"M Boufraqech","year":"2016","unstructured":"Boufraqech M, Zhang L, Nilubol N, Sadowski SM, Kotian S, Quezado M, et al. Lysyl oxidase (LOX) transcriptionally regulates SNAI2 expression and TIMP4 secretion in human cancers. Clin Cancer Res. 2016;22(17):4491\u2013504.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15691_CR18","doi-asserted-by":"publisher","first-page":"44988","DOI":"10.1038\/srep44988","volume":"7","author":"EP Cuevas","year":"2017","unstructured":"Cuevas EP, Eraso P, Maz\u00f3n MJ, Santos V, Moreno-Bueno G, Cano A, et al. LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway. Sci Rep. 2017;7(1):44988.","journal-title":"Sci Rep"},{"issue":"6","key":"15691_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1159\/000512520","volume":"211","author":"AR Subbalakshmi","year":"2022","unstructured":"Subbalakshmi AR, Sahoo S, Biswas K, Jolly MK. A computational systems biology approach identifies SLUG as a mediator of partial Epithelial-Mesenchymal Transition (EMT). Cells Tissues Organs. 2022;211(6):689\u2013702.","journal-title":"Cells Tissues Organs"},{"issue":"3","key":"15691_CR20","doi-asserted-by":"publisher","first-page":"e1005456","DOI":"10.1371\/journal.pcbi.1005456","volume":"13","author":"B Huang","year":"2017","unstructured":"Huang B, Lu M, Jia D, Ben-Jacob E, Levine H, Onuchic JN. Interrogating the topological robustness of gene regulatory circuits by randomization. PLoS Comput Biol. 2017;13(3):e1005456.","journal-title":"PLoS Comput Biol"},{"issue":"12","key":"15691_CR21","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739\u201340.","journal-title":"Bioinformatics"},{"issue":"2","key":"15691_CR22","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1186\/bcr3144","volume":"14","author":"C Zhou","year":"2012","unstructured":"Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012;14(2):R45.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"15691_CR23","doi-asserted-by":"publisher","first-page":"e0157290","DOI":"10.1371\/journal.pone.0157290","volume":"11","author":"M Carrier","year":"2016","unstructured":"Carrier M, Joint M, Lutzing R, Page A, Rochette-Egly C. Phosphoproteome and transcriptome of RA-responsive and RA-resistant breast cancer cell lines. PLoS ONE. 2016;11(6):e0157290.","journal-title":"PLoS ONE"},{"issue":"228","key":"15691_CR24","doi-asserted-by":"publisher","first-page":"20250116","DOI":"10.1098\/rsif.2025.0116","volume":"22","author":"Y Fan","year":"2025","unstructured":"Fan Y, George JT. Distinct evolutionary patterns of tumour-immune escape and elimination determined by extracellular matrix architectures. J R Soc Interface. 2025;22(228):20250116.","journal-title":"J R Soc Interface"},{"issue":"3","key":"15691_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nri.2015.16","volume":"16","author":"MF Krummel","year":"2016","unstructured":"Krummel MF, Bartumeus F, G\u00e9rard A. T cell migration, search strategies and mechanisms. Nat Rev Immunol. 2016;16(3):193\u2013201.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"15691_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1084\/jem.20061890","volume":"204","author":"A Boissonnas","year":"2007","unstructured":"Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med. 2007;204(2):345\u201356.","journal-title":"J Exp Med"},{"issue":"17","key":"15691_CR27","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","volume":"27","author":"M Taki","year":"2021","unstructured":"Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, et al. Tumor immune microenvironment during epithelial-mesenchymal transition. Clin Cancer Res. 2021;27(17):4669\u201379.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"15691_CR28","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.2014.57.8963","volume":"33","author":"AK Turnbull","year":"2015","unstructured":"Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, et al. Accurate prediction and validation of response to endocrine therapy in breast cancer. J Clin Oncol. 2015;33(20):2270\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15691_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12964-024-01492-2","volume":"22","author":"MA Caricasulo","year":"2024","unstructured":"Caricasulo MA, Zanetti A, Terao M, Garattini E, Paroni G. Cellular and micro-environmental responses influencing the antitumor activity of all-trans retinoic acid in breast cancer. Cell Commun Signal. 2024;22(1):127.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"15691_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1158\/0008-5472.CAN-19-2732","volume":"80","author":"JT George","year":"2020","unstructured":"George JT, Levine H. Sustained coevolution in a stochastic model of cancer-immune interaction. Cancer Res. 2020;80(4):811\u20139.","journal-title":"Cancer Res"},{"key":"15691_CR31","doi-asserted-by":"publisher","first-page":"e82786","DOI":"10.7554\/eLife.82786","volume":"12","author":"JT George","year":"2023","unstructured":"George JT, Levine H. Optimal cancer evasion in a dynamic immune microenvironment generates diverse post-escape tumor antigenicity profiles. Elife. 2023;12:e82786.","journal-title":"Elife"},{"issue":"11","key":"15691_CR32","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3390\/biom10111561","volume":"10","author":"D Sinha","year":"2020","unstructured":"Sinha D, Saha P, Samanta A, Bishayee A. Emerging concepts of hybrid epithelial-to-mesenchymal transition in cancer progression. Biomolecules. 2020;10(11):1561.","journal-title":"Biomolecules"},{"key":"15691_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ceb.2020.05.001","volume":"66","author":"ML Piacentino","year":"2020","unstructured":"Piacentino ML, Li Y, Bronner ME. Epithelial-to-mesenchymal transition and different migration strategies as viewed from the neural crest. Curr Opin Cell Biol. 2020;66:43\u201350.","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"15691_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"15691_CR35","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"15691_CR36","first-page":"524","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524\u201341.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"15691_CR37","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/cancers13061380","volume":"13","author":"Y Shlyakhtina","year":"2021","unstructured":"Shlyakhtina Y, Moran KL, Portal MM. Genetic and non-genetic mechanisms underlying cancer evolution. Cancers. 2021;13(6):1380.","journal-title":"Cancers"},{"key":"15691_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2018.09.007","volume":"194","author":"MK Jolly","year":"2019","unstructured":"Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, et al. Hybrid epithelial\/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol Ther. 2019;194:161\u201384.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"15691_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"15691_CR40","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-21-4370","volume":"82","author":"RD Mullins","year":"2022","unstructured":"Mullins RD, Pal A, Barrett TF, Heft Neal ME, Puram SV. Epithelial-mesenchymal plasticity in tumor immune evasion. Cancer Res. 2022;82(13):2329\u201343.","journal-title":"Cancer Res"},{"issue":"11","key":"15691_CR41","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.3390\/curroncol29110654","volume":"29","author":"S Muralidharan","year":"2022","unstructured":"Muralidharan S, Sehgal M, Soundharya R, Mandal S, Majumdar SS, Yeshwanth M, et al. PD-L1 activity is associated with partial EMT and metabolic reprogramming in carcinomas. Current Oncol. 2022;29(11):8285\u2013301.","journal-title":"Current Oncol"},{"issue":"1","key":"15691_CR42","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5(1):5241.","journal-title":"Nat Commun"},{"issue":"3","key":"15691_CR43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/1078-0432.CCR-15-0876","volume":"22","author":"MP Mak","year":"2016","unstructured":"Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res. 2016;22(3):609\u201320.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"15691_CR44","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","volume":"77","author":"A Dongre","year":"2017","unstructured":"Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77(15):3982\u20139.","journal-title":"Cancer Res"},{"issue":"14","key":"15691_CR45","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","volume":"22","author":"Y Lou","year":"2016","unstructured":"Lou Y, Diao L, Cuentas ERP, Denning WL, Chen L, Fan YH, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 2016;22(14):3630\u201342.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15691_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbcan.2018.10.003","volume":"1871","author":"E Tulchinsky","year":"2019","unstructured":"Tulchinsky E, Demidov O, Kriajevska M, Barlev NA, Imyanitov E. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Biophys Acta (BBA) - Rev Cancer. 2019;1871(1):29\u201339.","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"issue":"1","key":"15691_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41416-024-02698-4","volume":"131","author":"H Jeong","year":"2024","unstructured":"Jeong H, Koh J, Kim S, Song SG, Lee SH, Jeon Y, et al. Epithelial- mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. Brit J Cancer. 2024;131(1):23\u201336.","journal-title":"Brit J Cancer"},{"issue":"3","key":"15691_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.32607\/actanaturae.11010","volume":"12","author":"A Gaponova","year":"2020","unstructured":"Gaponova A, Rodin S, Mazina A, Volchkov P. Epithelial-mesenchymal transition: Role in cancer progression and the perspectives of antitumor treatment. Acta Naturae. 2020;12(3):4\u201323.","journal-title":"Acta Naturae"},{"issue":"4","key":"15691_CR49","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40291-023-00652-3","volume":"27","author":"I O\u2019Connell","year":"2023","unstructured":"O\u2019Connell I, Dongre A. Immune checkpoint blockade therapy for breast cancer: lessons from epithelial-mesenchymal transition. Mol Diagnosis Ther. 2023;27(4):433\u201344.","journal-title":"Mol Diagnosis Ther"},{"issue":"2","key":"15691_CR50","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cells9020428","volume":"9","author":"J Dudas","year":"2020","unstructured":"Dudas J, Ladanyi A, Ingruber J, Steinbichler TB, Riechelmann H. Epithelial to mesenchymal transition: A mechanism that fuels cancer radio\/chemoresistance. Cells. 2020;9(2):428.","journal-title":"Cells"},{"issue":"1","key":"15691_CR51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01634-6","volume":"18","author":"A Glaviano","year":"2025","unstructured":"Glaviano A, Lau HSH, Carter LM, Lee EHC, Lam HY, Okina E, et al. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J Hematol Oncol. 2025;18(1):6.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"15691_CR52","first-page":"832","volume":"3","author":"ML Lotsberg","year":"2020","unstructured":"Lotsberg ML, Rayford A, Thiery JP, Belleggia G, Peters SD, Lorens JB, et al. Decoding cancer\u2019s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. Cancer Drug Resist. 2020;3(4):832.","journal-title":"Cancer Drug Resist"},{"key":"15691_CR53","doi-asserted-by":"publisher","first-page":"768","DOI":"10.18632\/oncotarget.28666","volume":"15","author":"Y Fan","year":"2024","unstructured":"Fan Y, Chiu A, Zhao F, George JT. Understanding the interplay between extracellular matrix topology and tumor-immune interactions: Challenges and opportunities. Oncotarget. 2024;15:768.","journal-title":"Oncotarget"},{"issue":"1","key":"15691_CR54","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13(1):80.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"15691_CR55","doi-asserted-by":"publisher","first-page":"e006773","DOI":"10.1136\/jitc-2023-006773","volume":"11","author":"GT Clifton","year":"2023","unstructured":"Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP, et al. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer. 2023;11(6):e006773.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"15691_CR56","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12967-021-03002-1","volume":"19","author":"Z Zeng","year":"2021","unstructured":"Zeng Z, Li J, Zhang J, Li Y, Liu X, Chen J, et al. Immune and stromal scoring system associated with tumor microenvironment and prognosis: a gene-based multi-cancer analysis. J Transl Med. 2021;19(1):330.","journal-title":"J Transl Med"},{"key":"15691_CR57","doi-asserted-by":"crossref","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF$$\\beta $$ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","DOI":"10.1038\/nature25501"},{"key":"15691_CR58","doi-asserted-by":"publisher","first-page":"RP101885","DOI":"10.7554\/eLife.101885.3","volume":"13","author":"J Ackermann","year":"2025","unstructured":"Ackermann J, Bernard C, Sirven P, Salmon H, Fraldi M, Amar MDB. Mechanistic insight for T-cell exclusion by cancer-associated fibroblasts in human lung cancer. Elife. 2025;13:RP101885.","journal-title":"Elife"},{"key":"15691_CR59","doi-asserted-by":"crossref","unstructured":"Shrestha P, Fan Y, George JT. Coupled SDE-ODE Modeling of Tumor-Immune Dynamics to Infer Biomarker Release. bioRxiv. 2025.","DOI":"10.1101\/2025.08.15.670571"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15691-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:03:02Z","timestamp":1774886582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15691-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15691"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15691-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"420"}}